5-HT2 antagonist and 5-HT7 inverse agonist
brain penetrant, oral efficacy in rodent models
backup candidate to JNJ-18038683
Bioorg. Med. Chem. Lett., Nov. 7, 2020
Janssen, San Diego, CA
“compound 4j”
“compound 4j” (Janssen (JNJ) brain-penetrant in vivo 5-HT2 antagonist and 5-HT7 inverse agonist, backup candidate)